Corcept Therapeutics (CORT) Total Current Liabilities (2010 - 2026)

Corcept Therapeutics has reported Total Current Liabilities for 17 years, with the latest figure at $153.8 million in Q2 2026.

• Quarterly Total Current Liabilities rose 6.32% year-over-year to $153.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $153.8 million (up 6.32% YoY) and the FY2025 annual result came in at $166.1 million, up 17.98% from the prior year.
• Total Current Liabilities advanced to $153.8 million in Q2 2026 per CORT's latest filing, from $149.2 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $172.3 million in Q3 2025 and troughed at $49.1 million in Q2 2022.
• A 5-year average of $112.5 million and a median of $113.2 million in 2023 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2023 and 2024: Total Current Liabilities soared 129.65% in 2023, then grew 3.56% in 2024.
• Over 5 years, Total Current Liabilities stood at $72.5 million in 2022, then surged by 44.16% to $104.5 million in 2023, then soared by 34.7% to $140.8 million in 2024, then grew by 17.98% to $166.1 million in 2025, then retreated by 7.4% to $153.8 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $153.8 million, $149.2 million, and $166.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.